Managing the low inflation challenge
Nick Kirrage has begun adding supermarkets to the £1.5bn Schroder Income fund he co-manages with Kevin Murphy, expecting a significant boost to dividends in the long term.
Shares in UK-listed pharmaceutical giants Shire and AstraZeneca have fallen sharply this morning, after the US Treasury introduced a new law to curb tax avoidance by US companies which buy overseas rivals.
MERGERS AND ACQUISITIONS
The dangers of playing the momentum game
Neil Woodford is running his largest allocation to overseas stocks since 2013 as he begins management of his new UK equity income fund.
Top-performing Neptune mid-cap manager Mark Martin has been adding to ex-FTSE 250 companies following the latest index shake-up.
Neil Woodford's top ten holdings in his Woodford Equity Income fund contain few surprises, with AstraZeneca, GlaxoSmithKline and British American Tobacco the three largest positions.
Neil Woodford's new fund is a focal point of investor interest at the moment, but those looking to diversify their UK equity income exposure have a number of alternatives.
Lazard manager Pat Ryan is optimistic on the prospects for Chinese banks despite a string of well-publicised problems, and has increased exposure to the sector within his Global Equity Income fund.
Henderson's Chris Burvill is buying AstraZeneca, among other firms, in a move to benefit from merger and acquisition speculation.
M&A is messier than investors might like
US pharmaceutical giant Pfizer has abandoned its plans to buy AstraZeneca following an unsuccessful pursuit of its UK rival.
AXA IM has urged AstraZeneca to reconsider its rejection of a £69bn takeover bid by Pfizer as fund managers take opposing sides in advance of an imminent deadline for discussions to begin.
Shares in pharma giant AstraZeneca plunged this morning after the group rejected a fresh offer from US firm Pfizer.
EFG Asset Management is set to launch an M&A tracker fund led by global chief investment officer Mozamil Afzal, together with head of equity research Robin Milway.
The pace of the economic recovery in the UK has taken economists by surprise in the last year, prompting a number of upwards revisions for GDP growth.
The increased use of company shares to finance M&A activity may be a warning sign for investors that valuations are topping out, leading fund managers have said.
Pfizer, the US pharmaceuticals giant which today raised its offer for UK rival AstraZeneca, has written to Prime Minister David Cameron in an attempt to appease fears over the impact of any takeover.
US giant Pfizer has made an improved offer to buy AstraZeneca, the UK's second largest pharmaceuticals company, raising its bid to £50 a share.
Growth-focused UK equity managers have joined their income peers in backing pharmaceuticals as deals both real and rumoured send shares rocketing.
The FTSE 100 has risen in early trading as news of a fresh Pfizer approach for AstraZeneca sparks a 15% jump in the UK group's share price.
The FTSE 100 has risen 0.7% in early trading to touch its highest level in six weeks, driven by gains for pharmaceutical giant AstraZeneca and the mining sector.